Erasmus Medisch Centrum

Running trials

• Not yet recruiting

  Endoscopic (EID) Versus Surgical (TAMIS) Local Excision for Early Stage Rectal Cancer

  NCT07846046· Source

• Recruiting

  A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

  NCT07218380· Phase 3· Source

• Recruiting

  A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

  NCT07213804· Phase 3· Source

• Recruiting

  A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

  NCT07165028· Phase 3· Source

• Active, not recruiting

  A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

  NCT07005128· Phase 3· Source

• Active, not recruiting

  Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

  NCT07037433· Phase 3· Source

• Recruiting

  Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

  NCT06937099· Phase 3· Source

• Recruiting

  A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors

  NCT06914128· Phase 1/2· Source

• Recruiting

  Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

  NCT06731478· Phase 3· Source

• Recruiting

  Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

  NCT06472245· Phase 3· Source

• Recruiting

  Avapritinib Rollover Study

  NCT06748001· Phase 4· Source

• Recruiting

  Omentum Preservation Versus Complete Omentectomy in Gastrectomy for Gastric Cancer

  NCT05180864· Source

• Recruiting

  Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)

  NCT06095583· Phase 3· Source

• Active, not recruiting

  The UPDATE Trial (Uvb Phototherapy in Dermatology for ATopic Eczema)

  NCT05704205· Source

• Active, not recruiting

  A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)

  NCT05060016· Phase 2· Source

• Recruiting

  A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)

  NCT04844606· Phase 3· Source

• Active, not recruiting

  Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)

  NCT04663347· Phase 1/2· Source

• Active, not recruiting

  A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer

  NCT03706365· Phase 2/3· Source

• Active, not recruiting

  Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

  NCT01874353· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer3 recruiting
• Crohn's disease2 recruiting
• Gastric and esophageal cancer2 recruiting
• Bladder cancer1 recruiting
• Colorectal cancer1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• Glioblastoma1 recruiting
• Obesity1 recruiting
• Ovarian cancer1 recruiting
• Pancreatic cancer1 recruiting
• Ulcerative colitis1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Study in People With Pulmonary Fibrosis to Monitor Cough With a Wearable Device

  NCT05670587· Source

• Terminated

  Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia

  NCT05079230· Phase 3· Source

• Terminated

  GEN1047 for Solid Tumors - First in Human (FIH) Trial

  NCT05180474· Phase 1/2· Source

• Completed

  EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway

  NCT05093634· Phase 3· Source

• Completed

  DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway

  NCT04963231· Phase 2· Source

• Completed

  A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS)

  NCT04968912· Phase 2· Source

• Terminated

  Futibatinib in Patients With Specific FGFR Aberrations

  NCT04189445· Phase 2· Source

• Completed

  MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01)

  NCT04495621· Phase 1/2· Source

• Completed

  Digoxin Evaluation in Chronic Heart Failure: Investigational Study In Outpatients in the Netherlands

  NCT03783429· Phase 4· Source

• Terminated

  A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205

  NCT04241068· Phase 3· Source

• Completed

  Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).

  NCT04068181· Phase 2· Source

• Completed

  M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)

  NCT03631706· Phase 3· Source

• Completed

  A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease

  NCT02620046· Phase 3· Source

• Completed

  A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma

  NCT02451943· Phase 3· Source

• Completed

  LOWER: Lomitapide Observational Worldwide Evaluation Registry

  NCT02135705· Source